Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells

Oncogene

Volumn 31, Issue 34, 2012, Pages 3845-3856

  Khanal, P ^a,b   Yun, H J ^a,b   Lim, S C ^b   Ahn, S G ^a   Yoon, H E ^a   Kang, K W ^a   Hong, R ^b   Choi, H S ^a  

^a Chosun University   (South Korea)

^b Chosun University College of Medicine   (South Korea)

Author keywords

CDK10; Pin1; Raf 1; tamoxifen resistance; ubiquitination

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 10; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PEPTIDYLPROLYL ISOMERASE PIN1; RAF PROTEIN; SORAFENIB; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER GROWTH; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; EMBRYO; ENZYME DEGRADATION; FIBROBLAST; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CYCLIN-DEPENDENT KINASES; DRUG RESISTANCE, NEOPLASM; EMBRYO, MAMMALIAN; FIBROBLASTS; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; MICE; MICE, KNOCKOUT; PEPTIDYLPROLYL ISOMERASE; PHOSPHORYLATION; PROTEIN BINDING; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-RAF; RNA INTERFERENCE; TAMOXIFEN; UBIQUITIN;

EID: 84865443113     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.548     Document Type: Article

References (39)

1. Ali S, Coombes RC. (2002). Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2: 101-112. (Pubitemid 37328797)
2. Brambilla R, Draetta G. (1994). Molecular cloning of PISSLRE, a novel putative member of the cdk family of protein serine/threonine kinases. Oncogene 9: 3037-3041. (Pubitemid 24296783)
3. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y et al. (2003). Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22: 7316-7339. (Pubitemid 37492898)
4. Deroo BJ, Korach KS. (2006). Estrogen receptors and human disease. J Clin Invest 116: 561-570. (Pubitemid 43326860)
5. Dougherty MK, Muller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD et al. (2005). Regulation of Raf-1 by direct feedback phosphoryla-tion. Mol Cell 17: 215-224. (Pubitemid 40138617)
6. EBCTCG (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
7. El-Ashry D, Miller DL, Kharbanda S, Lippman ME, Kern FG. (1997). Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene 15: 423-435. (Pubitemid 27370992)
8. Finn G, Lu KP. (2008). Phosphorylation-specific prolyl isomerase Pin1 as a new diagnostic and therapeutic target for cancer. Curr Cancer Drug Targets 8: 223-229. (Pubitemid 351666858)
9. Giacinti L, Claudio PP, Lopez M, Giordano A. (2006). Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 11: 1-8. (Pubitemid 43152681)
10. Heller G, Ziegler B, Brandstetter A, Novak S, Rudas M, Hennig G et al. (2009). CDK10 is not a target for aberrant DNA methylation in breast cancer. Anticancer Res 29: 3939-3944.
11. Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M et al. (2008). Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13: 91-104. (Pubitemid 351163160)
12. Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS. (1994). Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 269: 4458-4466.
13. Lee M, Koh WS, Han SS. (2003). Down-regulation of Raf-1 kinase is associated with paclitaxel resistance in human breast cancer MCF-7/Adr cells. Cancer Lett 193: 57-64. (Pubitemid 36412079)
14. Li S, MacLachlan TK, De Luca A, Claudio PP, Condorelli G, Giordano A. (1995). The cdc-2-related kinase, PISSLRE, is essential for cell growth and acts in G2 phase of the cell cycle. Cancer Res 55: 3992-3995.
15. Lu KP. (2003). Prolyl isomerase Pin1 as a molecular target for cancer diagnostics and therapeutics. Cancer Cell 4: 175-180. (Pubitemid 37163831)
16. Lu KP, Hanes SD, Hunter T. (1996). A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 380: 544-547. (Pubitemid 26111332)
17. Lu KP, Liou YC, Zhou XZ. (2002). Pinning down proline-directed phosphorylation signaling. Trends Cell Biol 12: 164-172. (Pubitemid 34442238)
18. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S et al. (2008). Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68: 826-833. (Pubitemid 351206760)
19. McGlynn LM, Kirkegaard T, Edwards J, Tovey S, Cameron D, Twelves C et al. (2009). Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients. Clin Cancer Res 15: 1487-1495.
20. Morgan DO. (1997). Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13: 261-291. (Pubitemid 28034527)
21. Namgoong GM, Khanal P, Cho HG, Lim SC, Oh YK, Kang BS et al. (2010). The prolyl isomerase Pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer. J Biol Chem 285: 23829-23841.
22. Norbury C, Nurse P. (1992). Animal cell cycles and their control. Annu Rev Biochem 61: 441-470.
23. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D. (2001). Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 15: 1344-1359. (Pubitemid 32703482)
24. Osborne CK, Shou J, Massarweh S, Schiff R. (2005). Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11: 865s-870s. (Pubitemid 40111098)
25. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L et al. (1995). HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435-2446.
26. Riggs BL, Hartmann LC. (2003). Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348: 618-629. (Pubitemid 36210865)
27. Ryo A, Liou YC, Lu KP, Wulf G. (2003). Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer. J Cell Sci 116: 773-783. (Pubitemid 36367627)
28. Shang Y, Brown M. (2002). Molecular determinants for the tissue specificity of SERMs. Science 295: 2465-2468. (Pubitemid 34270263)
29. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H et al. (2004). Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96: 926-935. (Pubitemid 38868139)
30. Stanya KJ, Liu Y, Means AR, Kao HY. (2008). Cdk2 and Pin1 negatively regulate the transcriptional corepressor SMRT. J Cell Biol 183: 49-61.
31. Trowbridge JM, Rogatsky I, Garabedian MJ. (1997). Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proc Natl Acad Sci USA 94: 10132-10137. (Pubitemid 27407006)
32. Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G et al. (2011). HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Res Treat 130: 29-40.
33. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109. (Pubitemid 39331023)
34. Wulf G, Finn G, Suizu F, Lu KP. (2005). Phosphorylation-specific prolyl isomerization: is there an underlying theme? Nat Cell Biol 7: 435-441. (Pubitemid 40637396)
35. Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Petkova V et al. (2001). Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 20: 3459-3472. (Pubitemid 32634353)
36. Yaffe MB, Schutkowski M, Shen M, Zhou XZ, Stukenberg PT, Rahfeld JU et al. (1997). Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science 278: 1957-1960. (Pubitemid 28013239)
37. Yi P, Wu RC, Sandquist J, Wong J, Tsai SY, Tsai MJ et al. (2005). Peptidyl-prolyl isomerase 1 (Pin1) serves as a coactivator of steroid receptor by regulating the activity of phosphorylated steroid receptor coactivator 3 (SRC-3/AIB1). Mol Cell Biol 25: 9687-9699. (Pubitemid 41507865)
38. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ et al. (2004). Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 39: 1517-1524. (Pubitemid 38702652)
39. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ. (1997). CDK-independent activation of estrogen receptor by cyclin D1. Cell 88: 405-415. (Pubitemid 27131382)